{"id":"W2129967156","doi":"10.1177/1352458513507821","title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","year":2013,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Ottawa Hospital; University of Ottawa","funders":"IC Design Education Center; National Institutes of Health; Serono Symposia International Foundation; Bayer HealthCare; Acorda Therapeutics; Multiple Sclerosis Society; Biogen; Sanofi; National Multiple Sclerosis Society","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Discontinuation; Clinical endpoint; Dimethyl fumarate; Physical therapy; Expanded Disability Status Scale; Randomized controlled trial; Immunology; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001668686,0.001002676,0.002676651,0.001017554,0.0007617304,0.0006696999,0.000608525,0.0003542957,0.0008515451],"category_scores_gemma":[0.004402535,0.0007218892,0.0008712678,0.0006900968,0.0004866784,0.001046892,0.0002818845,0.001943178,0.0002032856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001149733,"about_ca_system_score_gemma":0.0003280901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004164772,"about_ca_topic_score_gemma":0.0003075267,"domain_scores_codex":[0.991806,0.0008599728,0.00243877,0.001051629,0.001960136,0.001883476],"domain_scores_gemma":[0.9932647,0.002471398,0.001003885,0.0008861713,0.001240671,0.00113313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8969072,0.003783567,0.04207423,0.0000566929,0.001045723,0.0000580346,0.0007686452,0.0001147147,0.02421548,6.712172e-7,0.00151533,0.02945968],"study_design_scores_gemma":[0.8662965,0.01470312,0.110903,0.001649006,0.0003782136,0.0000308614,0.0005711843,0.003804655,0.000834294,0.000002911316,0.0001456725,0.0006805909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864265,0.0005456572,0.0002387618,0.0007758016,0.001355856,0.01012526,0.00005379421,0.0001511186,0.0003273007],"genre_scores_gemma":[0.9940148,0.0006825185,0.002618049,0.0001964177,0.0007797004,0.001322013,0.00006642342,0.0001870988,0.0001329807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06882876,"threshold_uncertainty_score":0.9995232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08007616229311648,"score_gpt":0.2890024800529596,"score_spread":0.2089263177598432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}